Meiji Yasuda Life Insurance Co Increases Stake in Illumina, Inc. $ILMN

Posted by Geri Gentry on Aug 30th, 2026

Meiji Yasuda Life Insurance Co increased its stake in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 182.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,464 shares of the life sciences company’s stock after acquiring an additional 3,530 shares during the period. Meiji Yasuda Life Insurance Co’s holdings in Illumina were worth $961,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ILMN. Fiduciary Financial Advisors purchased a new position in Illumina during the second quarter worth approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $32,000. Rakuten Securities Inc. purchased a new stake in shares of Illumina during the 2nd quarter valued at $33,000. Elyxium Wealth LLC purchased a new stake in shares of Illumina during the 4th quarter valued at $25,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Illumina during the 4th quarter worth $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ILMN. Barclays lifted their target price on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Leerink Partners lifted their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Canaccord Genuity Group boosted their target price on Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Finally, Royal Bank Of Canada increased their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $188.40.

Check Out Our Latest Research Report on Illumina

Insider Activity

In other Illumina news, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 138,379 shares of the stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the sale, the director directly owned 1,033,910 shares in the company, valued at $236,651,659.90. This trade represents a 11.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 2,034,688 shares of company stock worth $417,970,281. 2.90% of the stock is currently owned by insiders.

Key Headlines Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Illumina’s second-quarter results showed continued operating momentum, with revenue of approximately $1.16 billion, up about 9.5% year over year, and earnings of $1.31 per share versus the $1.23 consensus estimate. Management also raised full-year revenue and non-GAAP EPS guidance. Should You Add Illumina Stock to Your Portfolio Now?
Positive Sentiment: Investors continue to point to growth in sequencing, oncology applications and multiomics as potential catalysts for ILMN, although cost volatility could pressure margins. Should You Add Illumina Stock to Your Portfolio Now?
Neutral Sentiment: Illumina disclosed a new $1.0 billion five-year revolving credit facility, but reported no borrowings outstanding, limiting the immediate balance-sheet implications.
Neutral Sentiment: Institutional positioning was mixed in the latest quarter, with major investors including FMR, Wellington and JPMorgan adding shares while other funds reduced holdings.
Negative Sentiment: Director Keith Meister disclosed several sales totaling hundreds of thousands of shares, including 106,543 shares sold for roughly $24.0 million and 138,379 shares sold for approximately $31.7 million. Repeated insider selling can weigh on sentiment, even though it does not necessarily signal deteriorating fundamentals. Insider Selling: Illumina Director Sells 106,543 Shares
Negative Sentiment: After climbing into the upper $220s and near its 52-week high, ILMN may be experiencing profit-taking. Valuation is also demanding, while reported analyst price targets generally remain below the recent trading level, increasing downside sensitivity if growth expectations cool.

Illumina Stock Performance

Illumina stock opened at $215.59 on Friday. The firm has a market capitalization of $32.55 billion, a PE ratio of 40.22, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81. The stock’s 50 day moving average price is $194.05 and its 200 day moving average price is $155.60. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

About Illumina

(Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.